The interventional oncology devices market size has grown strongly in recent years. It will grow from $2.5 billion in 2025 to $2.68 billion in 2026 at a compound annual growth rate (CAGR) of 7.1%. The growth in the historic period can be attributed to increasing cancer incidence rates, expansion of interventional radiology practices, improvements in imaging technologies, growing adoption of minimally invasive oncology treatments, availability of specialized oncology centers.
The interventional oncology devices market size is expected to see strong growth in the next few years. It will grow to $3.5 billion in 2030 at a compound annual growth rate (CAGR) of 7%. The growth in the forecast period can be attributed to increasing demand for targeted cancer therapies, rising investments in precision oncology, expansion of outpatient cancer treatment settings, growing adoption of combination interventional therapies, technological advancements in ablation and embolization devices. Major trends in the forecast period include increasing adoption of image-guided tumor ablation devices, rising use of minimally invasive cancer treatments, growing deployment of embolization therapies, expansion of precision oncology procedures, enhanced integration of advanced imaging support systems.
The high prevalence of cancer is anticipated to drive the growth of the interventional oncology devices market in the coming years. Cancer refers to a group of diseases marked by the uncontrolled growth and spread of abnormal cells within the body. These abnormal cells can form masses or tumors. The increasing prevalence of cancer raises the demand for interventional oncology devices, as they are used for the diagnosis, treatment, and management of cancer, supporting early detection, staging, and ongoing monitoring. For example, in July 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, the number of cancer cases diagnosed in Australia rose from 160,570 in 2022 to 164,694 in 2023, indicating a notable year-on-year increase. This upward trend underscores the growing prevalence of cancer in the country. Therefore, the high prevalence of cancer is contributing to the growth of the interventional oncology devices market.
Leading players operating in the interventional oncology devices market are emphasizing advanced technologies, such as tissue volume, to improve diagnostic precision and treatment effectiveness in oncology procedures. Tissue volume refers to the quantity of biological tissue obtained during a biopsy procedure. Collecting larger tissue volumes enables more comprehensive samples, thereby enhancing diagnostic accuracy and the effectiveness of treatment planning. For instance, in June 2023, Argon Medical, a US-based medical device company, introduced the SuperCore Advantage semi-automatic biopsy device. The SuperCore Advantage is capable of collecting up to 35% more samples compared to leading competitors, reducing the need for multiple biopsy passes. This capability is essential for obtaining sufficient tissue samples to support accurate diagnosis.
In May 2024, Siemens Healthineers, a Germany-based provider of devices and imaging systems supporting interventional oncology, entered into a partnership with University Hospitals to advance precision care through innovation and integrated clinical excellence. The collaboration aims to improve oncology, cardiovascular, and neurovascular outcomes by jointly advancing theranostics, novel MR technologies, and next-generation patient care solutions. University Hospitals is a US-based healthcare system.
Major companies operating in the interventional oncology devices market are Boston Scientific Corporation, Terumo Corporation, Siemens Healthineers, Sirtex Medical Limited, AngioDynamics Inc., Viant Medical, Medtronic plc, Olympus Corporation, Koninklijke Philips, Quantum Surgical, Profound Medical, Intuitive Surgical Inc, Cook Medical LLC, EDAP TMS S.A, Varian Medical Systems Inc, Heraeus Medical, ABLbio, Bioavlee, Mediceena International, LifeTech Scientific Corporation.
North America was the largest region in the interventional oncology devices market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the interventional oncology devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the interventional oncology devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are influencing the interventional oncology devices market by increasing costs of imported imaging systems, ablation probes, catheters, embolic materials, and electronic control components. Oncology centers and hospitals in North America and Europe are most affected due to reliance on specialized imported devices, while Asia-Pacific faces cost pressure on device manufacturing and exports. These tariffs are increasing capital expenditure for cancer treatment facilities. However, they are also encouraging domestic device innovation, regional manufacturing expansion, and localized supply chain development for oncology technologies.
The interventional oncology devices market research report is one of a series of new reports that provides interventional oncology devices market statistics, including interventional oncology devices industry global market size, regional shares, competitors with a interventional oncology devices market share, detailed interventional oncology devices market segments, market trends and opportunities, and any further data you may need to thrive in the interventional oncology devices industry. This interventional oncology devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Interventional oncology devices are specialized medical tools and technologies designed for the minimally invasive diagnosis and treatment of cancer. These devices enable direct targeting of tumors, allowing for treatments such as ablation or embolization, which focus on destroying cancer cells while preserving nearby healthy tissue.
The primary products within the field of interventional oncology devices include embolization devices, ablation devices, and support devices. Embolization devices are designed for the embolization of blood vessels associated with various tumors. These devices are employed in procedures such as thermal tumor ablation, non-thermal tumor ablation, transcatheter arterial chemoembolization (TACE), transcatheter arterial radioembolization (TARE), selective internal radiation therapy (SIRT), and transcatheter arterial embolization (TAE) or bland embolization. These procedures are applied in the treatment of various cancer types, including liver cancer, kidney cancer, lung cancer, bone cancer, and others.
The interventional oncology devices market consists of sales of embolization devices, ablation devices, and support devices. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The interventional oncology devices market size is expected to see strong growth in the next few years. It will grow to $3.5 billion in 2030 at a compound annual growth rate (CAGR) of 7%. The growth in the forecast period can be attributed to increasing demand for targeted cancer therapies, rising investments in precision oncology, expansion of outpatient cancer treatment settings, growing adoption of combination interventional therapies, technological advancements in ablation and embolization devices. Major trends in the forecast period include increasing adoption of image-guided tumor ablation devices, rising use of minimally invasive cancer treatments, growing deployment of embolization therapies, expansion of precision oncology procedures, enhanced integration of advanced imaging support systems.
The high prevalence of cancer is anticipated to drive the growth of the interventional oncology devices market in the coming years. Cancer refers to a group of diseases marked by the uncontrolled growth and spread of abnormal cells within the body. These abnormal cells can form masses or tumors. The increasing prevalence of cancer raises the demand for interventional oncology devices, as they are used for the diagnosis, treatment, and management of cancer, supporting early detection, staging, and ongoing monitoring. For example, in July 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, the number of cancer cases diagnosed in Australia rose from 160,570 in 2022 to 164,694 in 2023, indicating a notable year-on-year increase. This upward trend underscores the growing prevalence of cancer in the country. Therefore, the high prevalence of cancer is contributing to the growth of the interventional oncology devices market.
Leading players operating in the interventional oncology devices market are emphasizing advanced technologies, such as tissue volume, to improve diagnostic precision and treatment effectiveness in oncology procedures. Tissue volume refers to the quantity of biological tissue obtained during a biopsy procedure. Collecting larger tissue volumes enables more comprehensive samples, thereby enhancing diagnostic accuracy and the effectiveness of treatment planning. For instance, in June 2023, Argon Medical, a US-based medical device company, introduced the SuperCore Advantage semi-automatic biopsy device. The SuperCore Advantage is capable of collecting up to 35% more samples compared to leading competitors, reducing the need for multiple biopsy passes. This capability is essential for obtaining sufficient tissue samples to support accurate diagnosis.
In May 2024, Siemens Healthineers, a Germany-based provider of devices and imaging systems supporting interventional oncology, entered into a partnership with University Hospitals to advance precision care through innovation and integrated clinical excellence. The collaboration aims to improve oncology, cardiovascular, and neurovascular outcomes by jointly advancing theranostics, novel MR technologies, and next-generation patient care solutions. University Hospitals is a US-based healthcare system.
Major companies operating in the interventional oncology devices market are Boston Scientific Corporation, Terumo Corporation, Siemens Healthineers, Sirtex Medical Limited, AngioDynamics Inc., Viant Medical, Medtronic plc, Olympus Corporation, Koninklijke Philips, Quantum Surgical, Profound Medical, Intuitive Surgical Inc, Cook Medical LLC, EDAP TMS S.A, Varian Medical Systems Inc, Heraeus Medical, ABLbio, Bioavlee, Mediceena International, LifeTech Scientific Corporation.
North America was the largest region in the interventional oncology devices market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the interventional oncology devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the interventional oncology devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are influencing the interventional oncology devices market by increasing costs of imported imaging systems, ablation probes, catheters, embolic materials, and electronic control components. Oncology centers and hospitals in North America and Europe are most affected due to reliance on specialized imported devices, while Asia-Pacific faces cost pressure on device manufacturing and exports. These tariffs are increasing capital expenditure for cancer treatment facilities. However, they are also encouraging domestic device innovation, regional manufacturing expansion, and localized supply chain development for oncology technologies.
The interventional oncology devices market research report is one of a series of new reports that provides interventional oncology devices market statistics, including interventional oncology devices industry global market size, regional shares, competitors with a interventional oncology devices market share, detailed interventional oncology devices market segments, market trends and opportunities, and any further data you may need to thrive in the interventional oncology devices industry. This interventional oncology devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Interventional oncology devices are specialized medical tools and technologies designed for the minimally invasive diagnosis and treatment of cancer. These devices enable direct targeting of tumors, allowing for treatments such as ablation or embolization, which focus on destroying cancer cells while preserving nearby healthy tissue.
The primary products within the field of interventional oncology devices include embolization devices, ablation devices, and support devices. Embolization devices are designed for the embolization of blood vessels associated with various tumors. These devices are employed in procedures such as thermal tumor ablation, non-thermal tumor ablation, transcatheter arterial chemoembolization (TACE), transcatheter arterial radioembolization (TARE), selective internal radiation therapy (SIRT), and transcatheter arterial embolization (TAE) or bland embolization. These procedures are applied in the treatment of various cancer types, including liver cancer, kidney cancer, lung cancer, bone cancer, and others.
The interventional oncology devices market consists of sales of embolization devices, ablation devices, and support devices. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Interventional Oncology Devices Market Characteristics
3. Interventional Oncology Devices Market Supply Chain Analysis
4. Global Interventional Oncology Devices Market Trends and Strategies
5. Interventional Oncology Devices Market Analysis of End Use Industries
7. Global Interventional Oncology Devices Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Interventional Oncology Devices Total Addressable Market (TAM) Analysis for the Market
9. Interventional Oncology Devices Market Segmentation
10. Interventional Oncology Devices Market Regional and Country Analysis
11. Asia-Pacific Interventional Oncology Devices Market
12. China Interventional Oncology Devices Market
13. India Interventional Oncology Devices Market
14. Japan Interventional Oncology Devices Market
15. Australia Interventional Oncology Devices Market
16. Indonesia Interventional Oncology Devices Market
17. South Korea Interventional Oncology Devices Market
18. Taiwan Interventional Oncology Devices Market
19. South East Asia Interventional Oncology Devices Market
20. Western Europe Interventional Oncology Devices Market
21. UK Interventional Oncology Devices Market
22. Germany Interventional Oncology Devices Market
23. France Interventional Oncology Devices Market
24. Italy Interventional Oncology Devices Market
25. Spain Interventional Oncology Devices Market
26. Eastern Europe Interventional Oncology Devices Market
27. Russia Interventional Oncology Devices Market
28. North America Interventional Oncology Devices Market
29. USA Interventional Oncology Devices Market
30. Canada Interventional Oncology Devices Market
31. South America Interventional Oncology Devices Market
32. Brazil Interventional Oncology Devices Market
33. Middle East Interventional Oncology Devices Market
34. Africa Interventional Oncology Devices Market
36. Interventional Oncology Devices Market Competitive Landscape and Company Profiles
37. Interventional Oncology Devices Market Other Major and Innovative Companies
40. Interventional Oncology Devices Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Interventional Oncology Devices Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses interventional oncology devices market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for interventional oncology devices? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The interventional oncology devices market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Product: Embolization Devices; Ablation Devices; Support Devices2) By procedure: Thermal Tumor Ablation; Non-Thermal Tumor Ablation; Transcatheter Arterial Chemoembolization (TACE); Transcatheter Arterial Radioembolization (TARE); Selective Internal Radiation Therapy (SIRT); Transcatheter Arterial Embolization (TAE); Bland Embolization
3) By Cancer Type: Liver Cancer; Kidney Cancer; Lung Cancer; Bone Cancer; Other Cancer Types
Subsegments:
1) By Embolization Devices: Embolic Agents; Catheters For Embolization; Delivery Systems For Embolic Agents2) By Ablation Devices: Radiofrequency Ablation Devices; Microwave Ablation Devices; Cryoablation Devices; Laser Ablation Devices
3) By Support Devices: Imaging Guidance Systems; Access Devices; Fluid Management Systems
Companies Mentioned: Boston Scientific Corporation; Terumo Corporation; Siemens Healthineers; Sirtex Medical Limited; AngioDynamics Inc.; Viant Medical; Medtronic plc; Olympus Corporation; Koninklijke Philips; Quantum Surgical; Profound Medical; Intuitive Surgical Inc; Cook Medical LLC; EDAP TMS S.A; Varian Medical Systems Inc; Heraeus Medical; ABLbio; Bioavlee; Mediceena International; LifeTech Scientific Corporation
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Interventional Oncology Devices market report include:- Boston Scientific Corporation
- Terumo Corporation
- Siemens Healthineers
- Sirtex Medical Limited
- AngioDynamics Inc.
- Viant Medical
- Medtronic plc
- Olympus Corporation
- Koninklijke Philips
- Quantum Surgical
- Profound Medical
- Intuitive Surgical Inc
- Cook Medical LLC
- EDAP TMS S.A
- Varian Medical Systems Inc
- Heraeus Medical
- ABLbio
- Bioavlee
- Mediceena International
- LifeTech Scientific Corporation
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 2.68 Billion |
| Forecasted Market Value ( USD | $ 3.5 Billion |
| Compound Annual Growth Rate | 7.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 21 |
